Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO

NCT07152392 | Recruiting Phase 4

• 1 other identifier: ASAP-3
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO. IBI311 is a fully human monoclonal insulin-like growth factor-1 receptor inhibitory antibody. It has binding activity against IGF-1R positive cells, can block the binding of IGF-1 and IGF-2 to IGF-1R, and has a dose-dependent effect. It can inhibit the proliferation of HT29 cells caused by the activation of the IGF-1R signaling pathway. Meanwhile, it can dose-dependently inhibit the proliferation of orbital fibroblasts and the secretion of hyaluronic acid (HA) in patients with TAO. However, there are still significant gaps in the existing research evidence: There is a lack of reports on the efficacy and safety of IBI311 in inactive moderate to severe TAO patients. The aim of this clinical study is to:

1. 1.To evaluate the efficacy of IBI311 treatment in patients with inactive moderate to severe TAO.
2. 2.To observe the safety of IBI311 treatment in patients with inactive moderate to severe TAO.

Conditions

Thyroid Associated Ophthalmopathies

Keywords

IGF-1R; TED; MR Imaging

Outcome Measures

Primary Outcomes (3)

• Percentage of participants who were diplopia responders after 4 times and at the end of the treatment

  Diplopia responders were defined as percentage of participants with ≥ 1 class improvement of eye motility from baseline assessed by Gorman score. Gorman score: 1 = no diplopia, 2 =intermittent diplopia, 3 = inconstant (gaze-evoked) diplopia, 4 = constant diplopia in primary or reading position.

  up to 24 weeks

• Percentage of participants who were proptosis responders after 4 times and and the end of the treatment

  Proptosis responders were defined as subjects whose exophthalmos in the study eye decreased by ≥2 mm compared to the baseline, and whose exophthalmos in the contralateral eye did not deteriorate (increase by ≥2 mm) at the end of the treatment.

  up to 24 weeks

• Incidence and characterization of nonserious treatment emergent adverse events (TEAEs) during the treatment

  throughout the study period

Secondary Outcomes (3)

• Percentage of participants who were ATA categorical responders after 4 times and at the end of the treatment

  up to 24 weeks

• Change of GO-QoL from baseline after 4 times and at the end of the treatment

  up to 24 weeks

• Changes of the visual field in the dark areas from baseline after 4 times and at the end of the treatment

  up to 24 weeks

Other Outcomes (2)

• MR Imaging changes of orbital contents compared with the baseline after 4 times and at the end of the treatment

  up to 24 weeks

• Percentage of participants who underwent surgery throughout the study period

  throughout the study period

Study Arms (2)

IBI311

ACTIVE COMPARATOR

Participants with inactive thyroid ophthalmopathy will 8 infusions of IBI1311 (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions),The interval between each treatment is 3 weeks. After completing 4 treatments, observe for 3 months before entering the next stage of treatment。

Drug: IBI311

Follow-up

OTHER

Participants with inactive thyroid ophthalmopathy will only receive follow-up every six months.

Other: Follew-up

Interventions

IBI311 DRUG

IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 500-mg glass vials as a Injection solution containing.

IBI311

Follew-up OTHER

recived follow-up every six months

Follow-up

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed with TAO by Bartley criteria.
• Moderate to severe patients defined by EUGOGO.
• CAS \<3 (on the 7-item scale) for the study eye.
• Participant with intractable diplopia, or incomplete closure of both eyes, or requiring further surgical intervention.
• Participant with a strong willingness for further intervention.

You may not qualify if:

• Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision.
• Combined with other lesions in the orbit.
• Receive orbital radiotherapy or surgical treatment for TED, including orbital decompression, strabismus surgery and eyelid retraction correction.
• During the screening period, if either ear has a history of tinnitus or other hearing impairment; Or abnormal pure tone audiometry results (defined as an average bone conduction hearing threshold of ≥25 dB at 0.5, 1, 2, 4 kHz or a bone conduction hearing threshold of ≥40 dB at any frequency).
• At the time of screening, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times ULN, or accompanied by active hepatitis B (defined as HBsAg positive with HBV-DNA load greater than 1000 IU/ mL), or being receiving anti-hepatitis B virus treatment.
• During screening, the Glomerular Filtration Rate (GFR) was \< 30 ml/ min/1.73m2 (using the MDRD formula: GFR =186× serum creatinine (mg/ dl) -1.154× (age) -0.203× (0.742 \[if female\]), unit conversion of serum creatinine: 1 μmol/L=0.0113 mg/dL); 10) At the time of screening, there was poorly controlled diabetes (defined as glycated hemoglobin ≥7.0% at the time of screening, or a new diabetes drug \[oral or injection\] or a dose change of the current prescribed diabetes drug \> 10% within 60 days before screening).
• Screening for poorly controlled hypertension, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; Or adjust the antihypertensive drug (dosage or type of drug) within 30 days before screening; Evidence of renal artery stenosis or unstable blood pressure (including orthostatic hypotension, etc.).
• At the time of screening, the 12-lead ECG showed a heart rate of \< 50 beats/min or \> 100 beats/min. The ECG indicated active heart disease, or the researchers believed that the abnormal ECG at the time of screening would interfere with the interpretation of the ECG results in the subsequent follow-up process. Especially, QTcF \> 450 ms (for men) and QTcF \> 470 ms (for women) should be excluded.
• HIV antibody or HCV antibody positive individuals or those with active syphilis (defined as those with positive non-specific syphilis antibodies or those who need anti-syphilis treatment after consultation by the infectious disease department).
• Any major illness/condition or evidence of an unstable clinical condition that, in the investigators judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study.
• Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participants participation in the study.
• Pregnant or lactating.

Sponsors & Collaborators

• Shanghai Changzheng Hospital: lead

Study Sites (1)

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, 200003, China

RECRUITING

MeSH Terms

Conditions

Graves Ophthalmopathy; Insulin-Like Growth Factor I, Resistance To

Condition Hierarchy (Ancestors)

Eye Diseases, Hereditary; Eye Diseases; Graves Disease; Exophthalmos; Orbital Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Goiter; Thyroid Diseases; Endocrine System Diseases; Hyperthyroidism; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Tuo Li, Vice Professor

CONTACT

+86-13918507887; zoe_leeto@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy Director

Study Record Dates

• First Submitted: June 21, 2025
• First Posted: September 3, 2025
• Study Start: April 15, 2025
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): April 15, 2035
• Last Updated: September 3, 2025

Record last verified: 2025-08

Locations

CN (1)